false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Advance ...
Nanoparticle Delivery for PKD
Nanoparticle Delivery for PKD
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Yunji Chung described three nanoparticle platforms her USC lab is developing to deliver therapies for polycystic kidney disease (PKD): small kidney-targeting micelles, lipid nanoparticles (LNPs), and urinary extracellular vesicles (uEVs). By tuning particle properties and adding targeting peptides, the team aims to improve kidney and cell-specific delivery.<br /><br />Micelles have carried small-molecule drugs and RNA cargos, including in oral formulations, and reduced disease progression in mouse models. Collecting-duct-targeted LNPs delivered PKD2 mRNA and improved kidney measures and tissue features in diseased mice; early results also suggest PKD2 delivery may help in a PKD1 model. The lab is investigating uEVs from healthy urine as a naturally kidney-derived carrier. In experiments, these vesicles increased PKD1 and PKD2 expression, reduced disease-associated effects, and showed preliminary survival benefits in a severe autosomal recessive PKD model.<br /><br />Chung emphasized that effective treatment depends on getting the therapeutic to the right cells, and discussed the challenges of translating delivery technologies into clinical therapies. During questions, she noted that work comparing modified and unmodified mRNA is ongoing, and that the targeting peptide’s mechanism and potential independent effects require further study.
Asset Caption
Eun ji Chung, PhD
Meta Tag
Speaker
Eun ji Chung
Keywords
polycystic kidney disease
nanoparticle delivery
kidney-targeting micelles
lipid nanoparticles
urinary extracellular vesicles
PKD2 mRNA
targeting peptides
Eun ji Chung
×
Please select your language
1
English